Article Text

Download PDFPDF
EP1013 Overview of non-epithelial ovarian tumours: incidence and survival in the netherlands
  1. OL van der Hel1,
  2. M Timmermans1,2,3,
  3. AM van Altena4,
  4. RFPM Kruitwagen2,3,
  5. BFM Slangen2,3,
  6. GS Sonke5,
  7. KK van de Vijver6 and
  8. MA van der Aa1
  1. 1Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht
  2. 2Department of Obstetrics and Gynaecology, Maastricht University Medical Center
  3. 3School for Oncology and Developmental Biology, GROW, Maastricht
  4. 4Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen
  5. 5Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
  6. 6Department of Pathology, Ghent University Hospital, Cancer Research Institute Ghent (CRIG), Ghent, Belgium

Abstract

Introduction/Background About 5% of ovarian tumours have a non-epithelial histology, including germ cell tumours (GCTs), sex cord-stromal tumours (SCSTs), and sarcomas. Since the rarity of these non-epithelial ovarian tumours and the scarcity of population-based studies, the aim of this population-based study is to describe trends in incidence, treatment, and survival of these women in the Netherlands.

Methodology All Dutch women diagnosed with non-epithelial ovarian malignant tumours between 1989 and 2015 were identified from the Netherlands Cancer Registry. Demographics, tumour characteristics, and initial treatment were collected and overall survival was analysed.

Results A total of 1258 women were diagnosed with non-epithelial ovarian tumours in the Netherlands, including 752 GCTs (60%), 341 SCSTs (27%), and 165 sarcomas (13%). The European age standardized incidence rate (ESR) was 0.4 per 100,000 persons per year for GCTs, 0.2 for SCSTs and 0.1 for sarcomas. Approximately 97% of patients underwent surgical resection for the primary tumour, whereas 31% received systemic treatment and 3% radiotherapy. Five-year overall survival improved for all histologic subtypes between the late 1980’s until 2015: GCTs from 73% to 88% (p=0.03) SCSTs from 64% to 81% (p=0.57) and sarcomas from 20% to 29% (p=0.14).

Conclusion Malignant GCTs and SCSTs are rare and its incidence did not significantly change during the last decades. They have a good prognosis which also improved slightly. Women with primary sarcomas of the ovary are extremely rare and still have a poor prognosis.

Disclosure Nothing to disclose.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.